ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

Post-LOE

atovaquone and proguanil hydrochloride pediatric

Ichnos Glenmark Innovation

ANDAORALTABLET

Approved

Jan 2011

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE (atovaquone and proguanil hydrochloride pediatric) by Ichnos Glenmark Innovation is tablets, fixed-dose combination of atovaquone and proguanil hydrochloride is an antimalarial agent [see microbiology ()] . Approved for plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported, acute and 1 more indications. First approved in 2011.

Drug data last refreshed 23h ago

Mechanism of Action

tablets, fixed-dose combination of atovaquone and proguanil hydrochloride is an antimalarial agent [see Microbiology ()] .

Pharmacologic Class:

Antimalarial

Indications (4)

Plasmodium falciparum malaria including in areas where chloroquine resistance has been reported

Worked on ATOVAQUONE AND PROGUANIL HYDROCHLORIDE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.